Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Mar 27, 2023; 15(3): 430-439
Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.430
Table 1 The baseline characteristic analysis of the patients
Variables
Non-EIPL group, n = 75
EIPL group, n = 75
P value
Age in yr66.93 ± 9.3864.55 ± 8.220.099
Sex0.200
Male5158
Female2417
BMI in kg/m221.51 ± 2.2921.64 ± 3.340.786
Smoking status0.373
Yes5550
No2025
Tumor location0.260
Upper2114
Middle1117
Low4344
Differentiated grade0.121
High00
Middle5545
Low2030
T stage0.405
T342
T47173
N stage0.112
N01324
N11812
N21417
N33022
Tumor size in cm5.52 ± 2.215.37 ± 2.320.671
Borrmann classification0.100
II 714
III6861
CEA in g/L16.21 ± 78.0614.13 ± 35.880.834
Neutrophil count as 109/L3.49 ± 1.324.71 ± 8.390.215
Lymphocyte count as 109/L1.35 ± 0.471.76 ± 2.480.164
NLR3.02 ± 1.963.03 ± 2.200.989
Platelet as 109/L202.52 ± 61.39226.19 ± 90.940.064
Table 2 Outcomes after surgery
Variables
Non-EIPL group, n = 75
EIPL group, n = 75
P value
Type of surgery0.242
Total5561
Distal2014
Time, surgery to first flatus in d4.19 ± 0.993.95 ± 0.870.108
Postoperative hospital stay in d15.26 ± 3.1014.48 ± 1.970.072
Abdominal pain10/755/750.174
Ileus 15/753/750.003
Abdominal abscess9/751/750.009
Leakage5/752/750.246
Bleeding 6/753/750.302
Neutrophil count as 109/L10.36 ± 3.3210.03 ± 3.560.552
Lymphocyte cell as 109/L1.02 ± 0.631.00 ± 0.600.817
NLR13.48 ± 8.5511.87 ± 5.220.169
Platelet as 109/L171.00 ± 59.98179.73 ± 60.380.381
Table 3 Univariate analysis of overall survival
Variable
β
HR (95%CI)
P value
Sex0.5141.671 (0.983-2.841)0.058
Age0.0241.025 (0.994-1.056)0.114
EIPL/Non-EIPL-0.9910.371 (0.218,0.631)0.000
Tumor size0.1921.211 (1.088-1.348)0.000
Type of surgery 0.1851.203 (0.653-2.214)0.553
Tumor location0.0750.928 (0.689-1.250)0.622
Borrmann classification-1.4740.229 (0.072-0.731)0.013
Differentiated grade0.4910.612 (0.351-1.067)0.083
T stage1.2503.489 (1.094-11.130)0.035
N stage0.5351.707 (1.339-2.176)0.000
Vascular invasion-0.9540.385 (0.235-0.632)0.000
Table 4 Multivariate analysis of overall survival
Variable
β
HR (95%CI)
P value
EIPL/Non-EIPL-0.8610.423 (0.246-0.727)0.002
Tumor size0.1391.149 (1.025-1.289)0.017
Borrmann classification-0.2680.765 (0.211-2.775)0.684
T stage1.3954.034 (1.255-12.971)0.019
N stage0.3131.368 (1.034-1.811)0.029
Vascular invasion-0.6080.545 (0.317-0.935)0.027